A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval ... them a Novartis drug recently awarded accelerated approval.

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.

progressive kidney disease and a leading cause of kidney failure due to glomerular disease. The FDA early last year had granted conditional approval of the drug, subject to confirmatory study results.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

On Friday, the U.S. Food and Drug Administration approved ... progression of eczema. The FDA's approval is a "big win for ...

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...

The submission, made on Tuesday, aims to secure approval for OLC's use in treating hyperphosphatemia in patients with chronic kidney disease ... for the drug's potential launch. The FDA has ...

LOS ALTOS, Calif. - Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...